**Kansas Designates 7-OH Kratom Substances as Schedule I, Elevating Compliance Stakes for the Industry**

Kansas Designates 7-OH Kratom Substances as Schedule I, Elevating Compliance Stakes for the Industry

TOPEKA, KS – April 11, 2026 – In a significant move impacting the kratom industry, Kansas Governor Laura Kelly officially signed House Bill 2365 on April 10, 2026. This legislation amends the Uniform Controlled Substances Act (CSA) to designate "7-OH kratom related substances" as Schedule I controlled substances. This classification places these specific compounds, particularly 7-hydroxymitragynine (7-OH) and its synthetic derivatives, into the same legal category as highly restricted drugs such as heroin, LSD, and marijuana, signaling a high potential for abuse and a lack of accepted medical use.

While some earlier legislative discussions and news reports broadly suggested a blanket ban on all kratom, the enacted law specifically targets 7-OH kratom related substances. This distinction is crucial, as proponents and opponents of broader kratom bans have often highlighted the difference between the natural kratom leaf and its concentrated or synthesized derivatives. However, the inclusion of "kratom related substances" in the designation still casts a wide net that warrants immediate attention from all stakeholders.

Why This Matters to Kratom Merchants and Consumers

This legislative action has profound implications for both kratom merchants and consumers in Kansas and potentially nationwide. For merchants, the sale, possession, or distribution of products containing 7-OH kratom related substances is now explicitly illegal, carrying severe penalties commensurate with Schedule I controlled substances. This could lead to increased enforcement actions and legal risks for businesses that do not rigorously monitor their product formulations. Even businesses dealing in natural kratom products may face heightened scrutiny due to potential confusion or misinterpretation of the law by consumers and enforcement agencies.

Consumers in Kansas will find access to products containing 7-OH kratom related substances completely prohibited. Those who use natural kratom products may experience disruptions in availability or face uncertainty regarding the legality of their purchases, despite the law's specific focus on 7-OH derivatives. The U.S. Food and Drug Administration (FDA) has consistently stated that it has not approved kratom for medical use, a point often emphasized in discussions around state-level regulations.

Critical Compliance Implications

The designation of 7-OH kratom related substances as Schedule I substances ushers in a new era of stringent compliance requirements. Any merchant operating in or shipping to Kansas must immediately cease all activities involving products that contain these prohibited compounds. The legislative landscape around kratom is rapidly evolving, with jurisdictions like Kansas City, Missouri, already implementing bans on synthetic kratom (7-OH) and restricting natural kratom sales to adults over 21, coupled with licensing requirements for retailers. This trend underscores the need for proactive and robust compliance strategies.

What High-Risk Merchants Need to Know: COAs, Lab Testing, and Regulatory Compliance

For high-risk kratom merchants, adherence to strict quality control and transparency measures is no longer merely good practice—it's imperative for survival.

1. Mandatory Third-Party Lab Testing: Comprehensive, independent third-party lab testing is now non-negotiable. Merchants must ensure their products are rigorously tested for the absence of 7-OH kratom related substances and any other scheduled compounds. This testing should also screen for contaminants such as heavy metals, pesticides, and microbiological agents.
2. Certificates of Analysis (COAs): Every batch of kratom product must be accompanied by a detailed Certificate of Analysis (COA) from an accredited lab. These COAs must explicitly confirm the absence of prohibited substances and provide a complete alkaloid profile, along with contaminant screening results. Merchants must be prepared to present these COAs upon request from regulators or payment processors.
3. Ingredient Transparency and Labeling: Clear, accurate, and compliant labeling is essential. Product labels must transparently list all ingredients and provide accurate alkaloid content. Any claims made about the product must be substantiated and avoid any language that could be construed as medical claims, particularly given the FDA's stance.
4. Age Verification and Sales Restrictions: Even for natural kratom, merchants should implement robust age verification processes, adhering to a minimum age of 21 for sales, reflecting a growing industry standard and local regulations like those seen in Kansas City, Missouri.
5. Continuous Regulatory Monitoring: The legal status of kratom and its derivatives is subject to frequent change at both state and local levels. Merchants must continuously monitor legislative developments and adapt their operations accordingly.
6. Legal Counsel: Engaging with legal counsel experienced in controlled substances and dietary supplement regulations is highly advisable to navigate this complex and high-risk environment.

The Kansas ban on 7-OH kratom related substances serves as a stark reminder of the volatile regulatory climate surrounding kratom. For merchants, proactive compliance, rigorous testing, and transparent operations are paramount to mitigating risk and ensuring continued viability in a challenging market.